Drug Profile
LU 58463
Latest Information Update: 24 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott GmbH & Co. KG
- Class Antithrombotics; Peptides
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thromboembolism; Venous thrombosis
Most Recent Events
- 01 Aug 1997 Investigation in Thromboembolism (Unknown route)
- 01 Aug 1997 Investigation in Venous thrombosis (Unknown route)
- 03 Jun 1997 No-Development-Reported for Thromboembolism (Unknown route)